Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PLRZ Polyrizon Ltd.

休市中 10-02 16:00:00 EDT

9.61

-0.71

-6.88%

盘后9.61

+0.000.00%

19:30 EDT

最高10.87	最低9.15	成交量5.65万
今开10.56	昨收10.32	日振幅16.67%
总市值2,334万	流通市值2,049万	总股本242.86万
成交额56.06万	换手率2.65%	流通股本213.17万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":9.61,"timestamp":1790971200000,"preClose":10.32,"halted":0,"volume":56467,"hourTrading":{"tag":"盘后","latestPrice":9.61,"preClose":9.61,"latestTime":"19:30 EDT","volume":160,"amount":1580.8257,"timestamp":1790983803614,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.06879844961240318,"floatShares":2131700,"shares":2428604,"eps":-4.96,"marketStatus":"休市中","change":-0.71,"latestTime":"10-02 16:00:00 EDT","open":10.56,"high":10.87,"low":9.15,"amount":560645.709844,"amplitude":0.166667,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.96,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":10.32,"preHourTrading":{"tag":"盘前","latestPrice":10.89,"preClose":10.32,"latestTime":"08:41 EDT","volume":58,"amount":588.3114,"timestamp":1790944916200,"change":0.57,"changeRate":0.055233,"amplitude":0.073624},"postHourTrading":{"tag":"盘后","latestPrice":9.61,"preClose":9.61,"latestTime":"19:30 EDT","volume":160,"amount":1580.8257,"timestamp":1790983803614,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":9.481965086459832},"requestUrl":"/m/hq/s/PLRZ","defaultTab":"news","newsList":[{"id":"1132297876","title":"Polyrizon完成Nasarix™研究临床中心网络建设，向患者入组迈进","url":"https://stock-news.laohu8.com/highlight/detail?id=1132297876","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132297876?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:30","pubTimestamp":1787232625,"startTime":"0","endTime":"0","summary":"Polyrizon已成功构建Nasarix™研究的临床中心网络，并正稳步推进至患者入组阶段。这一里程碑式的进展，标志着该公司在鼻腔给药技术领域的研究又向前迈出了关键一步。随着临床站点网络的全面落成，Polyrizon现已具备启动患者招募工作的充分条件，为后续试验的顺利开展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105819292","title":"Polyrizon公布Nasarix™生物相容性项目成功结果，支持向首次人体临床试验迈进","url":"https://stock-news.laohu8.com/highlight/detail?id=1105819292","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105819292?lang=zh_cn&edition=full","pubTime":"2026-07-02 19:37","pubTimestamp":1782992238,"startTime":"0","endTime":"0","summary":"Polyrizon公司宣布，其Nasarix™生物相容性项目已取得积极成果。这一关键进展有力地支持了该项目向首次人体临床试验阶段推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174404710","title":"Polyrizon与Arrow Aviation签署函件协议 将MOU下的排他期及初期谈判期延长至6月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1174404710","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174404710?lang=zh_cn&edition=full","pubTime":"2026-06-06 04:25","pubTimestamp":1780691121,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. 与 Arrow Aviation 已正式签署一份函件协议。根据该协议，双方此前在谅解备忘录（MOU）框架下约定的排他性谈判期及初期谈判阶段，将一并延长至今年6月30日。此举旨在为双方就潜在合作事宜提供更充分的协商时间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162623204","title":"Polyrizon Ltd. 签署协议进行普通股及预融资认股权证的注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1162623204","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162623204?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:02","pubTimestamp":1775563325,"startTime":"0","endTime":"0","summary":"生物技术公司Polyrizon Ltd. (PLRZ) 近日宣布，该公司已达成最终协议，将通过注册直接发行的方式，向机构投资者发售其普通股及预融资认股权证。\n此次发行旨在为公司的重要研发项目及一般营运资金需求筹集资金。根据市场惯例，此次发行的完成仍需满足特定的交割条件。\n通过这种融资方式，Polyrizon Ltd. 期望能加速其在研管线的进展，并进一步巩固其财务状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PLRZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.polyrizon-biotech.com","stockEarnings":[{"period":"1week","weight":-0.1081},{"period":"1month","weight":-0.2318},{"period":"3month","weight":-0.3036},{"period":"6month","weight":-0.2045},{"period":"1year","weight":0.4694},{"period":"ytd","weight":0.1319}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Polyrizon Ltd.于2005年1月在以色列注册成立。该公司是一家处于发展阶段的生物技术公司，专门开发以鼻喷雾剂形式交付的创新医疗器械水凝胶，该水凝胶在鼻腔内形成一层薄薄的基于水凝胶的防护屏障，可以防止病毒和过敏原接触鼻上皮组织。该公司的C&C水凝胶技术由天然存在的构建块的混合物组成，以鼻喷雾剂的形式提供，并可用作“生物面具”，在鼻腔内有一层薄薄的防护屏障。该公司正在进一步开发其专有的C&C水凝胶技术的某些方面，例如生物粘附性和在鼻腔沉积部位的延长保留时间，以用于鼻内给药。该公司将其专注于API鼻腔给药的独立平台技术称为T&T。","exchange":"NASDAQ","name":"Polyrizon Ltd.","nameEN":"Polyrizon Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Polyrizon Ltd.(PLRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Polyrizon Ltd.,PLRZ,Polyrizon Ltd.股票,Polyrizon Ltd.股票老虎,Polyrizon Ltd.股票老虎国际,Polyrizon Ltd.行情,Polyrizon Ltd.股票行情,Polyrizon Ltd.股价,Polyrizon Ltd.股市,Polyrizon Ltd.股票价格,Polyrizon Ltd.股票交易,Polyrizon Ltd.股票购买,Polyrizon Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Polyrizon Ltd.(PLRZ)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Polyrizon Ltd.(PLRZ)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}